Careers  |  Sign In  |  Register

Latest Additions

By composing a systematic review of randomized clinical trials of patients with advanced melanoma, researchers were able to demonstrate that the risk for immune-related adverse effects (irAEs) is directly correlated with immune checkpoint inhibitor type. The meta-analysis, put together by Chin Yuang...

Guidance on Molecular Testing for the Treatment of NSCLC

Evaluating the Role of Molecular Testing in Lung Cancer

Nathan A. Pennell, MD, PhD, director of the Lung Cancer Medical Oncology Program at Taussig Cancer Institute at the Cleveland Clinic, emphasizes the importance of molecular testing before establishing a lung cancer treatment plan, particularly for nonsquamous non-small cell lung cancer (NSCLC) patients. Dr....
Jessica Bauman, MD, assistant professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, Temple Health, shares details regarding different RET-fusion mutations in non-small cell lung cancer (NSCLC), placing emphasis primarily on KIF5B, which is seen in the majority of cases discussed in...
In this panel discussion excerpt, Adam M. Brufsky, MD, PhD, of the University of Pittsburgh and Kashyap Patel, MD, of Carolina Blood and Cancer Care, discuss the role biosimilars can play in reducing costs while maintaining quality of care in patients with cancer, using metastatic lung cancer as a...
Based on results from an earlier study led by Dr Isamu Okamoto of the Graduate School of Medical Sciences at Kyushu University in Fukuoka, Japan that found progression-free survival and response rates in elderly patients with advanced non-small cell lung cancer (NSCLC) were better with docetaxel when...
In this video interview, Jonathan W. Goldman, MD, a health sciences clinical instructor in the Department of Medicine at the Jonsson Comprehensive Cancer Center Signal Transduction and Therapeutics Program at UCLA, discusses data regarding the use of immunotherapy for oncogene-driven non-small cell lung...
Doctors Drilon, Rotow, Stinchcombe, and Saxena participated in a roundtable discussion about therapies targeting certain biomarkers in patients with non-small cell lung cancer (NSCLC). The expert panel agrees that with the advent of approved and potentially promising treatments for specific mutations and...
In this video, Hatim Husain, MD, medical oncologist and associate professor of medicine for Moores Cancer Center at UCSD, explores how liquid biopsies are being incorporated into studies as end points to be considered when analyzing how plasma-based testing can impact progression-free survival (PFS) and...
In this video, Anna C Pavlick, DO, MBA, co-director of the Melanoma Program at NYU Langone Health’s Perlmutter Cancer Center, discusses whether targeted therapy or immunotherapy should be administered first in patients with melanoma with BRAF mutations. Learn more by clicking...
There has been an explosion of new data from targeted therapy studies since the 2017 publication of ASCO's full clinical practice guidelines regarding systemic therapy for patients with stage IV non-small cell lung cancer (NSCLC). In light of these important updates, the panel of experts responsible for...